There are different BiTEs targeting BCMA and CD3 (BI 836909, EM801 and JNJ-64007957), which have shown potent anti-MM activity in vitro and in vivo murine and monkey models of MM [50,51,52]. Here, TNFRSF17 is linked to Miyoshi myopathy.